-+ 0.00%
-+ 0.00%
-+ 0.00%

Anixa Biosciences Taps Curia To Provide Formulation Development Services For Anixa's Investigational Breast Cancer Vaccine In Preparation For Upcoming Phase 2 Clinical Trial

Benzinga·11/18/2026 13:27:11
Listen to the news

Collaboration to support development of a stable, scalable formulation for clinical development and potential commercialization

SAN JOSE, Calif., Nov. 18, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will work with Curia, a leading global contract development and manufacturing organization (CDMO), to provide formulation development services for Anixa's investigational breast cancer vaccine in preparation for its upcoming Phase 2 clinical trial. The vaccine is being developed in collaboration with Cleveland Clinic.